afimetoran], and Alzheimer's disease [Anti-MTBR Tau]. Now, dear Seeking Alpha readers, I want to draw your attention to the ...

Cassava Sciences (NASDAQ:SAVA) has tapped Freda Nassif as chief commercial officer, effective Nov. 18, 2024. Ms. Nassif is an ...

Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash positio ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Bristol Myers Squibb continues to enroll the ongoing Phase 2 clinical trial in approximately 475 patients with early Alzheimer's disease; primary completion expected in 2027 (NCT06268886) Bristol ...

Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinical development.

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

Just a few days after Biogen abandoned its tau-targeting Alzheimer's disease candidate gosuranemab, Bristol-Myers Squibb has opted into a rival drug, paying $80 million for rights to Prothena's ...

Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugsAppointment initiates ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November ...

PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.

Merck & Co. Inc. (NYSE: MRK) and TheBristol-Myers Squibb Co. (NYSE ... is targeting indicators for adjunctive schizophrenia ...